福里尔·拉德纳律师事务所合伙人凯尔·法吉特就 影响制药行业的主要法律议题向《Law360 》分享了见解。
在题为《2026年值得关注的药品定价之争》的文章中,法杰特评论了制药行业挑战医保药品价格谈判计划的努力。她表示:"目前普遍共识是,制药公司的诉讼进展并不顺利。"
联邦医疗保险和医疗补助创新中心(CMMI)很难推行覆盖全美50个州的解决方案,并将其称为强制性实验项目,"法杰特继续说道,"我能预见会出现反对意见,认为CMMI的最终举措并未真正遵循其应遵循的监管框架。"
在GLP-1诉讼方面,法盖特在题为《制药商围绕GLP-1药物展开多线法律战》的文章中指出,这些纠纷的影响远不止于GLP-1药物领域。
针对"盗版"或配制GLP-1药物的争议,法盖特补充道,药物配制案件为法院提供了一个机会,可以明确划分配制药物作为必要替代品与非法仿制品的界限,这可能对制药行业产生"巨大"影响。
(需要订阅)
相关新闻
January 29, 2026
In the News
Jason Levine Featured in Q&A on Litigation Finance and Antitrust Matters
Foley & Lardner LLP partner Jason Levine was interviewed by Legal Funding Journal, sharing his perspective on litigation finance and the antitrust landscape.
January 28, 2026
In the News
Danielle Whitley Appointed to JAX Chamber Board of Directors
Foley & Lardner LLP Jacksonville office managing partner Danielle Whitley was announced as a 2026 member of the board of directors for JAX Chamber, Jacksonville's leading business network.
January 28, 2026
In the News
Teresa Taylor Cautions Compliance Risks as U.S. Companies Re‑Enter Venezuela
Foley & Lardner LLP partner Teresa Taylor was quoted in the Compliance Week article, "Oil and gas executives mull the real costs of Venezuelan oil," detailing U.S. oil and gas companies considering renewed operations in Venezuela.